Highlights,Bristol Myers Squibb's shares rose following the FDA's approval of COBENFY, the first new schizophrenia treatment ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Pregnant women who do not get enough sleep may be at higher risk of having children with neurodevelopmental delays, a new ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback